KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Net Cash Flow (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Net Cash Flow readings, the most recent being $75.4 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 171275.0% to $75.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.1 million, a 63.06% decrease, with the full-year FY2025 number at $23.1 million, down 63.06% from a year prior.
  • Net Cash Flow hit $75.4 million in Q4 2025 for Esperion Therapeutics, up from $6.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $144.4 million in Q1 2024 to a low of -$87.0 million in Q1 2021.
  • Median Net Cash Flow over the past 5 years was -$25.5 million (2022), compared with a mean of -$6.9 million.
  • Biggest five-year swings in Net Cash Flow: crashed 2299.2% in 2022 and later surged 171275.0% in 2025.
  • Esperion Therapeutics' Net Cash Flow stood at $105.2 million in 2021, then tumbled by 180.43% to -$84.6 million in 2022, then soared by 61.49% to -$32.6 million in 2023, then soared by 100.14% to $44000.0 in 2024, then surged by 171275.0% to $75.4 million in 2025.
  • The last three reported values for Net Cash Flow were $75.4 million (Q4 2025), $6.4 million (Q3 2025), and -$28.6 million (Q2 2025) per Business Quant data.